awmsg logo



afamelanotide (Scenesse®)


Reference No. 634

Publication date:
23/03/2018


Appraisal information

afamelanotide (Scenesse®) 16 mg subcutaneous implant


Company: Clinuvel Pharmaceuticals Ltd
BNF category: Skin
NMG meeting date: 03/05/2017
AWMSG meeting date: 13/09/2017
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 1717
Ratification by Welsh Government: 22/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Afamelanotide (Scenesse®) is not recommended for use within NHS Wales for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The case for cost-effectiveness has not been proven
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download